NO20062146L - Nukleosidforbindelser for behandling av virusinfeksjoner - Google Patents

Nukleosidforbindelser for behandling av virusinfeksjoner

Info

Publication number
NO20062146L
NO20062146L NO20062146A NO20062146A NO20062146L NO 20062146 L NO20062146 L NO 20062146L NO 20062146 A NO20062146 A NO 20062146A NO 20062146 A NO20062146 A NO 20062146A NO 20062146 L NO20062146 L NO 20062146L
Authority
NO
Norway
Prior art keywords
viral infections
treatment
nucleoside compounds
compounds
virus
Prior art date
Application number
NO20062146A
Other languages
English (en)
Inventor
Natalia B Dyatkina
Christopher Don Roberts
Jesse D Keicher
Original Assignee
Genelabs Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34557362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20062146(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/861,090 external-priority patent/US7202223B2/en
Application filed by Genelabs Tech Inc filed Critical Genelabs Tech Inc
Publication of NO20062146L publication Critical patent/NO20062146L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Utgreid er forbindelser, sammensetninger og fremgangsmåter for å behandle virale infeksjoner forårsaket av en flaviviridae-familievirus slik som hepatitt-C-virus.
NO20062146A 2003-10-27 2006-05-12 Nukleosidforbindelser for behandling av virusinfeksjoner NO20062146L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51515303P 2003-10-27 2003-10-27
US10/861,090 US7202223B2 (en) 2003-10-27 2004-06-04 Nucleoside compounds for treating viral infections
US60281504P 2004-08-18 2004-08-18
PCT/US2004/034955 WO2005042556A1 (en) 2003-10-27 2004-10-20 Nucleoside compounds for treating viral infections

Publications (1)

Publication Number Publication Date
NO20062146L true NO20062146L (no) 2006-07-21

Family

ID=34557362

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062146A NO20062146L (no) 2003-10-27 2006-05-12 Nukleosidforbindelser for behandling av virusinfeksjoner

Country Status (15)

Country Link
US (1) US7157434B2 (no)
EP (1) EP1680436A1 (no)
JP (1) JP2007509939A (no)
KR (1) KR20060096487A (no)
AR (1) AR046202A1 (no)
AU (1) AU2004285923A1 (no)
BR (1) BRPI0415883A (no)
CA (1) CA2542776A1 (no)
IL (1) IL174685A0 (no)
MX (1) MXPA06004680A (no)
NO (1) NO20062146L (no)
SV (1) SV2005001920A (no)
TW (3) TW200524606A (no)
UY (1) UY28581A1 (no)
WO (1) WO2005042556A1 (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PY0111577A (es) * 2000-05-23 2017-01-02 Idenix Cayman Ltd Métodos y composiciones para el tratamiento del virus de la hepatitis c
AP2006003708A0 (en) * 2000-05-26 2006-08-31 Idenix Cayman Ltd Methods and compositions for treating flavivirusesand pestiviruses
CN1678326A (zh) * 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
RU2005118421A (ru) * 2002-11-15 2006-01-20 Айденикс (Кайман) Лимитед (Ky) 2'-разветвленные нуклеозиды и мутация flaviviridae
PL377287A1 (pl) * 2002-12-12 2006-01-23 Idenix (Cayman) Limited Sposób wytwarzania 2'-rozgałęzionych nukleozydów
EP1689383B1 (en) 2003-11-19 2012-10-31 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US20050182252A1 (en) * 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
WO2006121468A1 (en) 2004-11-22 2006-11-16 Genelabs Technologies, Inc. 5-nitro-nucleoside compounds for treating viral infections
BRPI0607770A2 (pt) 2005-02-28 2009-06-13 Genelabs Tech Inc compostos de nucleosideo tricìclico para tratamento de infecções virais
WO2007084157A2 (en) * 2005-03-23 2007-07-26 Genelabs Technologies, Inc. Nucleoside prodrugs for treating viral infections
WO2006102594A1 (en) * 2005-03-23 2006-09-28 Genelabs Technologies, Inc. Nucleoside prodrugs for treating viral infections
TW200720285A (en) * 2005-04-25 2007-06-01 Genelabs Tech Inc Nucleoside compounds for treating viral infections
CA2606499C (en) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
KR101510065B1 (ko) 2005-06-08 2015-04-07 다나-파버 캔서 인스티튜트 인크. 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
JP5254033B2 (ja) * 2005-12-23 2013-08-07 イデニク プハルマセウティカルス，インコーポレイテッド 分岐型ヌクレオシドを調製するための合成中間体の製造方法
US8071568B2 (en) * 2007-01-05 2011-12-06 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
TW200838550A (en) * 2007-02-09 2008-10-01 Novartis Ag Organic compounds
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
GB0709791D0 (en) * 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
WO2010015637A1 (en) * 2008-08-06 2010-02-11 Novartis Ag New antiviral modified nucleosides
EP2370593B1 (en) 2008-11-28 2016-03-30 Emory University Methods for determining the efficacy of pd-1 antagonists
CL2009002206A1 (es) * 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
PT2421879E (pt) * 2009-04-22 2013-12-09 Acad Of Science Czech Republic Novos 7-deazapurina nucleósidos para utilizações terapêuticas
KR102182663B1 (ko) 2010-05-28 2020-11-25 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
US10017763B2 (en) 2010-09-03 2018-07-10 Sarepta Therapeutics, Inc. dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups
GEP20156313B (en) * 2010-09-22 2015-07-10 Alios Biopharma Inc Substituted nucleotide analogs
JP2015500204A (ja) 2011-11-18 2015-01-05 サレプタ セラピューティクス， インコーポレイテッド 機能的に修飾されたオリゴヌクレオチドおよびそのサブユニット
BR112015025766A2 (pt) 2013-04-12 2017-10-17 Achillion Pharmaceuticals Inc derivado de nucleosídeo altamente ativo para o tratamento de hcv
KR101974254B1 (ko) 2013-07-18 2019-04-30 다이호야쿠힌고교 가부시키가이샤 Fgfr 저해제의 간헐 투여용 항종양제
EP2947086B1 (en) 2013-08-12 2018-01-03 Taiho Pharmaceutical Co., Ltd. Novel fused pyrimidine compound or salt thereof
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
CA3044059A1 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
EA201992703A1 (ru) 2017-06-05 2020-04-15 Вайкинг Терапьютикс, Инк. Композиции для лечения фиброза
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途
CA3094167A1 (en) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140851A (en) * 1977-11-21 1979-02-20 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis and antitumor activity of 2,4,5-trisubstituted-pyrrolo2,3-d]-pyrimidine nucleosides
JPS61229897A (ja) 1985-04-05 1986-10-14 Nippon Zoki Pharmaceut Co Ltd 新規ヌクレオシド化合物
US6211158B1 (en) * 1987-04-10 2001-04-03 Roche Diagnostics Gmbh Desazapurine-nucleotide derivatives, processes for the preparation thereof, pharmaceutical compositions containing them and the use thereof for nucleic acid sequencing and as antiviral agents
US4892865A (en) * 1987-12-01 1990-01-09 The Regents Of The University Of Michigan Pyrrolo[2,3-d]pyrimidine nucleosides as antiviral agents
US4927830A (en) * 1988-04-08 1990-05-22 The Regents Of The University Of Michigan Acyclic pyrrolo[2,3-D]pyrimidine analogs as antiviral agents
US4968686A (en) * 1988-04-08 1990-11-06 The Regents Of The University Of Michigan Acyclic pyrrolo [2,3-d]pyrimidine analogs as antiviral agents
US5824796A (en) * 1988-09-28 1998-10-20 Epoch Pharmaceuticals, Inc. Cross-linking oligonucleotides
US5763597A (en) * 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. Orally active adenosine kinase inhibitors
HUT63170A (en) 1990-01-11 1993-07-28 Isis Pharmaceuticals Inc Process and composition for detecting and modifying rna activity and gene expression
US5681941A (en) * 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
AU673055B2 (en) 1993-02-03 1996-10-24 Gensia, Inc. Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
EP0695306A1 (en) 1993-04-19 1996-02-07 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
WO1995007919A1 (en) 1993-09-17 1995-03-23 Gilead Sciences, Inc. Method for dosing therapeutic compounds
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
DE4438918A1 (de) * 1994-11-04 1996-05-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
US6150510A (en) * 1995-11-06 2000-11-21 Aventis Pharma Deutschland Gmbh Modified oligonucleotides, their preparation and their use
US6004939A (en) * 1995-07-06 1999-12-21 Ctrc Research Foundation Board Of Regents Methods for modulation and inhibition of telomerase
AU6485996A (en) * 1995-07-06 1997-02-05 Board Of Regents, The University Of Texas System Methods and compositions for modulation and inhibition of teomerase
FR2750435B1 (fr) 1996-06-27 1998-08-28 Appligene Oncor Procede de formation de complexes d'hybridation dont la stabilite depend peu de la composition en base des deux molecules d'acides nucleiques hybridees
US6831069B2 (en) * 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
EP1138689A1 (en) 2000-03-28 2001-10-04 Roche Diagnostics GmbH N8- and C8-linked purine bases as universal nucleosides used for oligonucleotide hybridization
PY0111577A (es) 2000-05-23 2017-01-02 Idenix Cayman Ltd Métodos y composiciones para el tratamiento del virus de la hepatitis c
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
SI1355916T1 (sl) * 2001-01-22 2007-04-30 Merck & Co Inc Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
AU2002353165A1 (en) 2001-12-17 2003-06-30 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
AU2002364216A1 (en) 2001-12-21 2003-07-15 Micrologix Biotech Inc. Anti-viral 7-deaza l-nucleosides
WO2003062256A1 (en) * 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
WO2003068244A1 (en) * 2002-02-13 2003-08-21 Merck & Co., Inc. Methods of inhibiting orthopoxvirus replication with nucleoside compounds
WO2003099840A1 (en) * 2002-05-24 2003-12-04 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
AU2003241621A1 (en) * 2002-05-24 2003-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
AU2003269902A1 (en) 2002-07-16 2004-02-02 Isis Pharmaceuticals, Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
EP1527082A2 (en) 2002-07-25 2005-05-04 Micrologix Biotech, Inc. Anti-viral 7-deaza d-nucleosides and uses thereof
US7094768B2 (en) * 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
US7425547B2 (en) 2002-09-30 2008-09-16 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
AU2003291682A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations

Also Published As

Publication number Publication date
JP2007509939A (ja) 2007-04-19
SV2005001920A (es) 2005-08-18
CA2542776A1 (en) 2005-05-12
KR20060096487A (ko) 2006-09-11
US7157434B2 (en) 2007-01-02
UY28581A1 (es) 2005-05-31
TW200528466A (en) 2005-09-01
TW200524606A (en) 2005-08-01
MXPA06004680A (es) 2007-04-17
AR046202A1 (es) 2005-11-30
TW200524587A (en) 2005-08-01
EP1680436A1 (en) 2006-07-19
US20050107312A1 (en) 2005-05-19
WO2005042556A1 (en) 2005-05-12
BRPI0415883A (pt) 2007-01-09
AU2004285923A1 (en) 2005-05-12
IL174685A0 (en) 2006-08-20

Similar Documents

Publication Publication Date Title
TW200602064A (en) Nucleoside derivatives for treating hepatitis C virus infection
NO20045247L (no) Nukleosidderivater for behandling av hepatitt C-virusinfeksjon
BRPI0415883A (pt) compostos e composições de nucleosìdeo para o tratamento de infecções virais
EA200500584A1 (ru) Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c
NO20070751L (no) Inhibitorer av HCV-replifikasjon
TW200720285A (en) Nucleoside compounds for treating viral infections
NO20092053L (no) HCV NS3-proteaseinhibitorer
NO20074613L (no) Tricykliske nukleosidforbindelser for behandling av virale infeksjoner
EA201000201A1 (ru) Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
TW200517381A (en) Bicyclic heteroaryl derivatives
NO20073849L (no) Indolderivater for behandling av virale infeksjoner
NO20080879L (no) HCV-NS3-proteaseinhibitorer
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
DK1569929T3 (da) Forbindelser og fremgangsmåder til behandling eller forebyggelse af flavi-virusinfektioner
EA200702493A1 (ru) Соединения и способы лечения или предотвращения флавивирусных инфекций
EA200501689A1 (ru) Соединения в качестве ингибиторов вируса гепатита c
EA200900298A1 (ru) Ингибиторы вируса гепатита с
TW200745035A (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
EA200900297A1 (ru) Ингибиторы вируса гепатита с
NO20073105L (no) Pyridazinonforbindelser
NO20070194L (no) Fremgangsmater for behandling av hepatitt C
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
TW200719898A (en) 6-membered aryl and heteroaryl derivatives for treating viruses
EA201000277A1 (ru) Соединения для лечения гепатита с
UY27798A1 (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatits c y composiciones y tratamientos que los usan.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application